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Susceptibility and protection against human autoimmune diseases, including type I 
diabetes, multiple sclerosis and Goodpasture’s disease, is associated with particular 
Human Leukocyte Antigen (HLA) alleles. However, the mechanisms underpinning such 
HLA-mediated effects on self-tolerance remain unclear. Here we investigated the 
molecular mechanism of Goodpasture’s disease, an HLA-linked autoimmune renal 
disorder characterized by an immunodominant CD4
+
 T cell self-epitope derived from 
the a3 chain of Type IV collagen (a3135-145)
1-4
. While HLA-DR15 confers a markedly 
increased disease risk, the protective HLA-DR1 allele is dominantly protective in trans 
with HLA-DR15
2
. We show that autoreactive a3135-145-specific T cells expand in patients 
with Goodpasture’s disease and, in a3135-145-immunized HLA-DR15 transgenic mice, 
a3135-145-specific T cells infiltrate the kidney and mice develop Goodpasture’s disease. 
HLA-DR15 and HLA-DR1 exhibited distinct peptide repertoires and binding 
preferences and presented the a3135-145 epitope in different binding registers. HLA-
DR15-a3135-145 tetramer
+
 T cells in HLA-DR15 transgenic mice exhibit a conventional T 
cell phenotype (Tconv) that secretes pro-inflammatory cytokines. In contrast, HLA-
DR1-a3135-145 tetramer
+
 T cells in HLA-DR1 and HLA-DR15/DR1 transgenic mice are 
predominantly CD4
+
Foxp3
+
 regulatory T cells (Tregs) expressing tolerogenic cytokines. 
HLA-DR1-induced Tregs confer resistance to disease in HLA-DR15/DR1 transgenic 
mice. HLA-DR15
+
 and HLA-DR1
+
 healthy human donors displayed altered a3135-145-
specific TCR usage, HLA-DR15-a3135-145 tetramer
+
 Foxp3
-
 Tconv and HLA-DR1-a3135-
145 tetramer
+
 Foxp3
+
CD25
hi
CD127
lo
 Treg dominant phenotypes, and patients with 
Goodpasture’s disease display a clonally expanded a3135-145-specific CD4
+
 T cell 
repertoire. Accordingly, we provide a mechanistic basis for the dominantly protective 
effect of HLA in autoimmune disease, whereby
 
HLA polymorphism shapes the relative 
abundance of self-epitope specific Tregs that leads to protection or causation of 
autoimmunity. 
 
Using HLA-DR15-a3135-145 tetramers, we found that a3135-145-specific CD4
+ T cells in 
peripheral blood of HLA-DR15+ Goodpasture’s patients are ~100-fold more frequent than in 
healthy HLA-DR15+ donors. Tregs can be important in limiting this disease5, but in 7 of 8 
patients the HLA-DR15-a3135-145-specific T cells were mainly Foxp3
- Tconv (Fig. 1a, 
Extended Data Table 1). HLA-DR15-a3135-145 tetramer
+ CD4+ T cells from all patients 
recognized a3135-145 and a3(IV)NC1 ex vivo (Extended Data Fig. 1a). After a3135-145 
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immunization, HLA-DR15-a3135-145-specific CD4
+ T cells infiltrated diseased kidneys in 
DR15+.Fcgr2b-/- mice, with the majority of these cells being Foxp3- (Fig. 1b, Extended Data 
Fig. 1b and 1c). a3135-145 immunized DR15
+.Fcgr2b+/+ mice, but not HLA-DR1 expressing 
DR1+.Fcgr2b+/+ mice, make pro-inflammatory responses after ex vivo stimulation with a3135-145 
or a3(IV)NC1, consistent with the lower risk of anti-GBM disease in humans2. Furthermore, 
in DR15+DR1+.Fcgr2b+/+ mice, a3135-145 immunization did not induce pro-inflammatory 
autoreactivity to a3135-145, or a3(IV)NC1 (Fig. 1c). DR15
+, DR1+ and DR15+DR1+ mice had 
similar overall HLA expression, similar overall proportions of Foxp3+ cells and no TCR Vb 
skewing of their entire CD4+ cell repertoire (Extended Data Fig. 2a). The dominant negative 
effect of HLA-DR1 was specific to the area of a3(IV)NC1 containing the immunodominant 
a3136-146 sequence (Extended Data Fig. 2b). Thus, HLA-DR15 restricted pro-inflammatory 
autoreactivity to a3135-145 is abrogated by co-expression of the HLA-DR1 allele. 
 
Next we characterised the self-peptide repertoires of the HLA-DR15 and HLA-DR1 
allomorphs6-9 from naïve DR15+ and DR1+ mice10-12. 5965 HLA-DR15 and 7015 HLA-DR1 
bound peptides were identified from which consensus peptide binding motifs were derived 
using IceLogo11 (Fig. 1d). Coincident with the canonical HLA-DR peptide anchor positions 
P1, P4, P6/7 and P9, the peptide positions p1, p4, p6 and p9 showed strong but distinct amino 
acid preferences for HLA-DR15 and HLA-DR1. Findings were similar using human 
DR15/DR51, and DR1 expressing cell lines (Extended Data Fig. 3a, 3b and 
Supplementary Data). 
 
We hypothesized that the polymorphisms between HLA-DR15 and HLA-DR1 affect the 
presentation of a3135-145. Here, 9 out of the 13 polymorphic differences reside within the Ag 
binding cleft (Fig. 2a). We solved the structures of HLA-DR15-a3135-145 and HLA-DR1-
a3135-145 (Extended Data Table 2 & Extended Data Fig. 3c-f). The overall structures of 
HLA-DR15 and HLA-DR1 were closely matched (0.6 Å r.m.s.d. over 360 Ca-atoms, Fig. 
2a). In HLA-DR15-a3135-145 the peptide binding register of a3135-145 was GWISLWKGFSF 
(pHLA positions p1 to p9 underlined), and thus the canonical HLA-DR peptide binding 
pockets were occupied by the peptide sidechains of p1-Ile, p4-Trp, p7-Phe and p9-Phe (Fig. 
2b). This peptide binding register was in agreement with the peptide elution data (Fig. 1d). 
Each of the anchor residues (p1-Ile, p4-Trp and p7-Phe) made direct interactions with one or 
more polymorphic residues of HLA-DR15. Namely, p1-Ile was buried inside the P1 pocket, 
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where it contacted the polymorphic Val86 (Figs. 2b and 2e). p4-Trp lay flat in the P4 pocket 
and interacted with the polymorphic residues Arg13, Phe26, Asp28 and Ala71. In the 
adjacent P6/7 pocket, p7-Phe contacted the polymorphic residues Asp28, Tyr30, Phe47 and 
Ile67. Notably, the P4 and P6/7 pockets were not structurally separated which appeared to be 
reflected in the enrichment of bulky and aromatic residues in p4 and p7 of HLA-DR15 eluted 
peptides (Fig. 1d). 
 
The peptide binding register of HLA-DR1-a3135-145, GWISLWKGFSF was distinct from 
HLA-DR15-a3135-145, i.e. it was shifted by one position towards the peptide N-terminus (Fig 
2c). Interestingly, the binding of MBP85-99 to HLA-DR51 is characterized by a 3 amino acid 
register shift compared with its binding to HLA-DR1513. Overlay of the peptides bound by 
HLA-DR15 and HLA-DR1 showed a difference in the peptide backbone conformations 
largely attributable to a flipped peptide bond between p5 and p6, resulting in differences of 
p6, p7 and p8 Ca-positions of 2.2 Å, 2.5 Å and 1.5 Å, respectively (Fig. 2d). The peptide in 
HLA-DR1-a3135-145 was anchored via the residues p1, p4, p6 and p9. The register shift was 
accompanied with a positional switch of the peptide anchor residue residing in the P6/P7 
pocket (p6-Lys in HLA-DR1 and p7-Phe in HLA-DR15). The observed peptide binding 
register shift was in agreement with the peptide elution data of HLA-DR1 (Fig. 1d), as it 
placed the preferred anchor residues p1-Trp and p4-Leu in the P1 and P4 pockets, 
respectively (Figs. 2c and 2f). Compared to P1 of HLA-DR15, the P1 pocket of HLA-DR1 
had a 190 Å3 larger volume due to the polymorphic residue Gly86 (Val86 in HLA-DR15). 
This allowed P1 of HLA-DR1 to accommodate p1-Trp, whilst P1 of HLA-DR15 would be 
unable to accommodate a Trp residue. The P4 and P6/7 pockets of HLA-DR1 were 
structurally segregated by the polymorphic residue Arg71 (Ala71 in HLA-DR15). This 
restricted the available space in the P4 pocket when compared to HLA-DR15. Compared to 
HLA-DR15, P6/7 of HLA-DR1 provided additional space underneath the peptide due to the 
presence of Cys30 and Phe13 (Tyr30 and Arg13 in HLA-DR15). Therefore, differences in 
shape and aperture of the P6/7 pocket allowed p6-Lys to reach underneath the peptide and act 
as a peptide anchor residue in HLA-DR1 forming a salt bridge with Glu28 (Fig. 2f), whereas 
HLA-DR15 p7-Phe bound laterally with respect to the peptide. Thus, the dominant negative 
effect of HLA-DR1 in anti-GBM disease is accompanied by register-shifted binding of a3135-
145 to HLA-DR1 and consequently a distinctly different peptide-HLA landscape. 
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We next addressed whether this altered pHLA landscape caused differences in the responding 
T cell repertoire (Fig. 2g). Namely, HLA-DR1-a3135-145 restricted T cells from DR1
+
 mice 
were more likely to bear TRAV14 than HLA-DR15-a3135-145
+
 T cells from DR15
+
 mice. In 
contrast, HLA-DR15-a3135-145 restricted TCRs exhibited TRBV bias, with TRBV19 present 
in 17/100 T cells, but absent in the HLA-DR1-a3135-145 T cell repertoire. Notably, 
experiments in DR15+DR1+ mice showing DR1-a3135-145 TRAV14 usage and DR15-a3135-145 
TRBV19 usage demonstrated that even in the presence of both HLA-DR15 and HLA-DR1, 
a3135-145-specific TCR usage is determined by the individual HLA molecule in a similar 
manner to mice transgenic for either HLA-DR15 or HLA-DR1 (Fig. 2g). We also found 
significant differences in the overall TCR distribution in the TRAJ region usage in the a3135-
145 TCR repertoire between DR15
+ and DR1+ mice (Extended Data Fig. 4a). These findings 
demonstrate that the altered pHLA landscapes result in differences in the responding T cell 
repertoire 
 
Next, we ascertained whether differences in a3135-145-specific TCR usage between HLA-
DR15 and HLA-DR1 were accompanied by functional phenotypic differences. We found that 
CD4+ T cells specific for this epitope from naive DR15+ mice were largely CD4+Foxp3- 
conventional T cells (Tconvs). In contrast, in DR1+ mice, a3135-145-specific CD4
+Foxp3+ 
Tregs were predominant, with their gene expression pattern being consistent with thymically 
derived tTregs (Extended Data Fig. 4b). In DR15+DR1+ mice, HLA-DR15-a3135-145 
tetramer+ CD4+ cells were largely Foxp3- Tconvs and those that bound the HLA-DR1-a3135-
145 tetramer were largely Foxp3
+ Tregs (Fig. 3a). Culture of naive CD4+ cells and syngeneic 
APCs with or without a3135-145 peptide showed that a3135-145-specific cells from DR15
+ mice 
produced interferon-g (IFN-g), interleukin-17A (IL-17A) and IL-6, whereas those from DR1+ 
and DR15+DR1+ mice did not produce these pathogenic T helper cell 1 (Th1) and Th17 
cytokines (Fig. 3b)4,14. When CD4+CD25+ Tregs were removed prior to culture, pro-
inflammatory a3135-145-specific responses emerged in DR15
+DR1+ mice, but not in DR1+ 
mice (Fig. 3b) indicating that in cultures from DR15+DR1+ mice, Tregs prevent the 
development of a3135-145-specific pro-inflammatory responses. When Tregs were present in 
DR1+ and in DR15+DR1+ mice, Foxp3+ Tregs proliferated in an antigen specific manner and 
secreted IL-10 and transforming growth factor-b (TGF-b) in response to a3135-145 peptide 
(Fig. 3b, Extended Data Fig. 5a). Furthermore, Tregs from DR1+ mice were substantially 
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more potent in suppressing the development of a3136-146-induced responses in CD4
+CD25- T 
cells from DR15+DR1+ mice when they included a3135-145-specific Tregs (Extended Data 
Fig. 5b). Therefore, HLA-DR1’s dominant protection from the HLA-DR15 conferred risk of 
anti-GBM disease is via the induction of a3135-145-specific Tregs. 
 
We assessed the capacity of Tregs in vivo to prevent autoimmunity to a3135-145 using HLA 
transgenic mice in experimental Goodpasture’s disease. Consistent with the in vitro findings 
(Fig. 3b), HLA-DR15+ mice developed reactivity towards a3135-145, with or without Treg 
depletion, while even after Treg depletion DR1+ mice did not develop pro-inflammatory 
reactivity to a3135-145 after immunization with this peptide. However, in DR15
+DR1+ mice, 
Treg depletion unmasked significant autoreactivity, with evidence of Th1 and Th17 
responses (Fig. 3c)4,14. Furthermore, Treg depletion in DR15+DR1+ mice resulted in an 
expanded population of HLA-DR15-a3135-145 tetramer
+ T follicular helper (Tfh) cells after 
immunization (Extended Data Fig. 5c), which would permit the induction of the classical 
anti-GBM (anti-a3(IV)NC1) autoantibodies found in this disease. To determine if Treg 
depletion unmasks Goodpasture’s disease itself in the presence of both HLA-DR15 and 
HLA-DR1, we immunized DR15+.Fcgr2b-/-, DR1+.Fcgr2b-/- and DR15+DR1+.Fcgr2b-/- mice with 
a3135-145 peptide, with or without Treg depletion (Fig. 4a,). In Treg depleted mice, 
CD4+Foxp3+ Tregs were reduced at days 7 and 14 during the development of autoimmunity, 
but restored by day 21 (Extended Data Fig. 6a) and mice immunized with a control peptide 
(OVA323-339) did not develop disease (Extended Data Fig. 6b). DR15
+.Fcgr2b-/- mice 
developed anti-GBM disease (Fig. 4a, Extended Data Fig. 6c and 6d), with no significant 
increase in most parameters after early Treg depletion. DR1+.Fcgr2b-/- mice were protected 
from disease after a3135-145 immunization and Treg depletion did not provoke renal disease. 
DR15+DR1+.Fcgr2b-/- mice did not develop disease, demonstrating the dominant protection of 
HLA-DR1 in vivo in this system. Critically, after Treg depletion a3135-145 immunized 
DR15+DR1+.Fcgr2b-/- mice developed severe glomerulonephritis of similar severity to 
DR15+.Fcgr2b-/- mice, phenotypically similar to human anti-GBM disease, with the classical 
and diagnostic serum anti-a3(IV)NC1 autoantibodies and IgG deposition on the GBM as 
well as glomerular infiltration of effector cells and elevated mRNA for intrarenal pro-
inflammatory cytokines (Fig. 4a, Extended Data Fig. 6c and 6d). Therefore, endogenous 
HLA-DR1-associated a3135-145-specific Tregs abrogate the DR15 mediated increased risk of 
developing Goodpasture’s disease and dominantly protect from this autoimmune disease. 
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Next we examined a3135-145-specific CD4
+ T cells from fully HLA-typed healthy blood 
donors who were either HLA-DR15 homozygotes, HLA-DR1 homozygotes or DR15/DR1 
heterozygotes (Extended Data Table 3). The HLA-DR15-a3135-145-specific CD4
+ T cells 
from donors homozygous for HLA-DR15 were largely Foxp3- Tconvs, those in people 
homozygous for DR1 were Foxp3+CD25hiCD127lo Tregs, while in DR15/DR1 heterozygotes, 
the HLA-DR15-a3135-145 tetramer
+ CD4+ T cells were Tconvs and HLA-DR1-a3135-145 
tetramer+ CD4+ T cells were Tregs (Fig. 4b). Only CD4+ cells from healthy HLA-DR15 
homozygote donors secreted pro-inflammatory cytokines in response to a3135-145 in the 
presence of Tregs. When CD25hiCD127lo cells were removed prior to culture, pro-
inflammatory responses emerged in T cells from DR15/DR1 heterozygotes, but not HLA-
DR1 homozygote healthy donors, while in the context of DR1 Tregs exhibited a3135-145-
specific proliferation and cytokine production (Fig. 4c). The a3135-145-specific CD4
+ T cell 
repertoire also showed evidence of skewing, in the TRBV gene usage (Extended Data Fig. 
7a). We also examined the a3135-145-specific TCR repertoire in the peripheral blood of two 
Goodpasture’s patients with acute disease and found that conserved HLA-DR15-a3135-145-
specific CD4+ TCR sequences were present in both the TRAV and TRBV regions (Extended 
Data Fig. 7b) of both patients, particularly in patient GP1 who exhibited identical sequences 
in 6/12 TRAV and 4/16 TRBV analyses. The repeat sequences in HLA-DR15-a3135-145 
tetramer+ CD4+ T cells in patients with Goodpasture’s disease provide further evidence that 
the a3135-145 epitope plays a pivotal role in this disease. 
 
Other autoimmune diseases with HLA associations, including type I diabetes and multiple 
sclerosis have reported dominantly protective or modulatory HLA alleles15-17. Presently, the 
mechanisms underpinning such dominant protective HLA effects are unclear, although 
several theories, including epitope capture, T cell deletion and Treg dominance have been 
proposed. Here, we have used Goodpasture’s disease as a model human autoimmune disease 
to mechanistically determine how an HLA allele can exert its dominant protective effect. Our 
structural and T cell repertoire data show that neither epitope capture nor T cell deletion are 
the mechanisms at play here. Instead, the dominant protective effect of HLA-DR1 is 
associated with a3135-145-specific Tregs. In Goodpasture’s disease, a register shift in the 
binding of the immunodominant autoreactive peptide to HLA-DR1 compared to HLA-DR15 
leads to fundamental differences between their CD4+ a3135-145-specific TCR repertoire and 
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phenotype. Our studies therefore provide a mechanistic basis for understanding HLA-
mediated susceptibility and protection in autoimmune disease. 
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FIGURE LEGENDS 
Figure 1: a3135-145 induces nephritogenic autoimmunity, but not when DR1 is co-
expressed. a, a3135-145-specific Foxp3
- effector CD4+ T cells in DR15+ healthy humans 
(n=7), and Goodpasture’s (GP) patients (n=8). b, a3135-145-specific effector CD4
+ T cells in 
kidneys from a3135-145-immunized DR15
+.Fcgr2b-/- mice (n=5 each group). c, HLA-DR1 co-
expression prevents pro-inflammatory autoreactivity to the GP antigen in a3135-145-
immunized DR15+DR1+.Fcgr2b+/+ mice (n=4 each group). d, Peptide repertoire analyses of 
HLA-DR presented self-peptides in DR15+ and DR1+ transgenic mice. Enriched and depleted 
amino acids are above and below the horizontal bar, respectively, scale of letter proportional 
to frequency difference. Values are mean±s.e.m.; *P<0.05; **P<0.01; ***P<0.001 by Mann-
Whitney U test (a, b) or Kruskal-Wallis test (c). 
 
Figure 2: Presentation of a3135-145 by HLA-DR15 and HLA-DR1. a, Polymorphisms (red) 
with the  b-chains of HLA-DR15 (light blue) and HLA-DR1 (light yellow). b-f, HLA-DR15-
a3135-145 and HLA-DR1-a3135-145 with HLA-DR a-chain (light green). Black, red and brown 
dashes represent H-bonds, salt-bridges, and peptide pocket positions, respectively. b, HLA-
DR15-a3135-145
 
c, HLA-DR-a3135-145. d, HLA-DR15 and HLA-DR1 alignment. e, HLA-
DR15 and DR1 polymorphisms (f) and interactions with a3135-145. g, TRAV and TRVB chain 
usage of a3135-145-specific CD4
+ T cells in HLA-DR transgenic mice (pooled samples, n=3 
mice each group), and phenotyping for Va2 (TRAV14) and Vb6 (TRBV19). Frequencies of 
TCRs between DR15 and DR1 were compared by Fisher’s exact test *** P<0.001. For flow 
cytometry, n=4 individual mice per group, *P<0.05, *** P<0.001 by unpaired two-tailed t-test. 
 
Figure 3: DR15 selects a3135-145-specific Tconvs but DR1 selects protective Tregs. a, 
a3135-145-specific CD4
+ T cells from naïve HLA-DR transgenic mice are predominantly 
Tconv (Foxp3-) in the context of HLA-DR15, but Tregs (Foxp3+) are selected by HLA-DR1. 
b, Naive CD4+ T cells from DR15+ mice with intact Tregs stimulated by a3135-145 secrete pro-
inflammatory cytokines, cells from DR1+ and DR15+DR1+ mice secrete tolerogenic 
cytokines, but without Tregs, T cells from DR15+ mice become autoreactive. Only in cells 
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from mice bearing HLA-DR1 does a3135-145 induce Treg proliferation. Cells were pooled 
from three mice of each strain, representative of three independent experiments performed in 
triplicate. c, In vivo depletion of Tregs results in autoreactivity in immunized 
DR15+DR1+.Fcgr2b+/+ mice (n=4 each group). Values are mean±s.e.m.; *P<0.05, **P<0.01, 
***
P<0.001 by Mann Whitney U test. 
 
Figure 4: Treg depletion unmasks disease in DR15
+
DR1
+.Fcgr2b-/-
 mice and autoimmunity 
in humans in vitro. a, Treg depletion before a3135-145 immunization leads to anti-GBM 
glomerulonephritis in DR15+DR1+.Fcgr2b-/- mice (DR15+.Fcgr2b-/- n=6 each group, DR1+ Fcgr2b-/- 
n=4 each group and DR15+DR1+.Fcgr2b-/- n=8 [Treg intact], 9 [Treg depleted]). Scale bars = 30 
µm. b, In the blood of healthy HLA-typed humans, a3135-145-specific CD4
+ Tconv cells 
predominate in the setting of DR15 and Tregs with DR1. c, In humans, only CD4+ T cells 
from healthy DR15 homozygotes (n=6) exhibit pro-inflammatory autoreactivity to a3135-145 
when Tregs are present, while Tregs in DR1 homozygotes (n=5) and DR15/DR1 
heterozygotes (n=5) proliferate and secrete tolerogenic cytokines. Values are mean±s.e.m.; 
*
P<0.05; **P<0.01; ***P<0.001, by unpaired two-tailed t-test (a, c top panels), Mann Whitney 
U test (b) and Kruskal-Wallis test (c, bottom panel). 
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METHODS 
Human subjects. Patients who were included in the study all had Goodpasture’s disease and 
fulfilled the key diagnostic criteria: 1) serum anti-a3(IV)NC1 IgG by ELISA, 2) linear IgG 
staining of the GBM and 3) necrotizing and crescentic glomerulonephritis. HLA-DR15 
typing of patients was done by monoclonal antibody staining (BIH0596, One Lambda) and 
flow cytometry. Blood from HLA-typed healthy humans was collected via the Australian 
Bone Marrow Donor Registry (ABMDR). HLA-DR15, HLA-DR1 and HLA-DR15/DR1 
donors were molecularly typed and were excluded if they expressed DQB1*03:02, which is 
potentially weakly associated with susceptibility to anti-GBM disease2. Studies were 
approved by the ABMDR and Monash Health Research Ethics Committees, and informed 
consent was obtained from each individual. 
 
Humanised HLA transgenic mice. Mouse MHCII deficient, DR15 transgenic mice and 
mouse MHCII deficient, DR1 transgenic mice were derived from existing HLA transgenic 
colonies and intercrossed so that they are on the same background as previously described4. 
Background: 50% C57BL/10, 43.8% C57BL/6, 6.2% DBA/2; or with an Fcgr2b-/- 
background: 72% C57BL/6, 25% C57BL/10 and 3% DBA/2. To generate mice transgenic for 
both HLA-DR15 and HLA-DR1 mice transgenic for either HLA-DR15 or HLA-DR1 were 
intercrossed. FcgRIIb intact HLA transgenic mice and cells were used for all experiments, 
except experiments in experimental Goodpasture’s disease, where Fcgr2b-/- HLA transgenic 
strains were used. While DR15+ mice readily break tolerance to a3(IV)NC1 when 
immunized with human a3135-145 or mouse a3136-146, renal disease is mild
4. As genetic 
changes in Fc receptors have been implicated in the development of nephritis in rodents and 
in humans18, Fcgr2b-/- HLA transgenic strains were used when end organ injury was an 
important endpoint. Experiments were approved by the Monash University Animal Ethics 
Committee (MMCB2011/05 and MMCB2013/21). 
 
Expression and purification of recombinant HLA-DR molecules. HLA-DR15-a3135-145 
and HLA-DR1-a3135-145 were produced in High Five insect cells (Trichoplusia ni BTI-TN-
5B1-4 cells, Invitrogen) using the baculovirus expression system essentially as described 
previously for HLA-DQ2/DQ8 proteins19,20. Briefly, synthetic DNA (Integrated DNA 
Technologies, IA) encoding the a- and b-chain extracellular domains of HLA-DR15 (HLA-
DR1A*0101, HLA-DRB1*15:01) HLA-DR1 (HLA-DR1A*0101, HLA-DRB1*01:01), and 
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the a3135-145 peptide were cloned into the pZIP3 baculovirus vector
19,20. To promote correct 
pairing, the C-termini of the HLA-DR15 and HLA-DR1 a- and b-chain encode enterokinase 
cleavable Fos and Jun leucine zippers, respectively. The b-chains also encoded a C-terminal 
BirA ligase recognition sequence for biotinylation and a poly-histidine tag for purification. 
HLA-DR15-a3135-145 and HLA-DR1-a3135-145 were purified from baculovirus infected High 
Five insect cell supernatants via successive steps of immobilized metal ion affinity (Ni 
Sepharose 6 Fast-Flow, GE Healthcare), size exclusion (S200 Superdex 16/600, GE 
Healthcare) and anion-exchange (HiTrap Q HP, GE Healthcare) chromatography. For 
crystallization, the leucine zipper and associated tags were removed by enterokinase 
digestion (Genscript, NJ) further purified by anion exchange chromatography, buffer 
exchanged into 10 mM Tris, pH 8.0, 150 mM NaCl and concentrated to 7 mg/ml. 
 
Tetramer generation and sample analysis. Purified HLA-DR15-a3135-145 and HLA-DR1-
a3135-145 proteins were buffer exchanged into 10 mM Tris pH 8.0, biotinylated using BirA 
ligase and tetramers assembled by addition of Streptavidin-PE (BD Biosciences) as 
previously described19. In mice, 107 splenocytes or cells from kidneys digested with 5 mg/ml 
collagenase D (Roche Diagnostics, Indianapolis, IN) and 100 mg/ml DNase I (Roche 
Diagnostics) in HBBS (Sigma-Aldrich) for 30 minutes at 37°C, filtered, erythrocytes lysed, 
and the CD45+ leukocyte population isolated by MACS using mouse CD45 microbeads 
(Miltenyi Biotec), were surface stained with Pacific Blue labeled anti-mouse CD4 (BD), 
APC-Cy7 labeled anti-mouse CD8 (BioLegend) and 10 nM of PE-labeled tetramer. Cells 
were then incubated with a Live/Dead fixable Near IR Dead Cell Stain (Thermo Scientific), 
permeabilized using a Foxp3 Fix/Perm Buffer Set (BioLegend), and stained with Alexa Fluor 
647 labeled anti-mouse foxp3 antibody (FJK16s). To determine Va2 and Vb6 usage, cells 
were stained with PerCP/Cy5.5 anti-mouse Va2 (B20.1, Biolegend) and APC labelled anti-
mouse Vb6 (RR4-7, Biolegend). For each mouse a minimum of 100 cells were analysed. The 
tetramer+ gate was set based on the CD8+ population. In humans, 3x107 white blood cells 
were surface stained with BV510 labeled anti-human CD3 (BioLegend), Pacific Blue labeled 
anti-human CD4 (BioLegend), PE-Cy7 labelled anti-human CD127 (BioLegend), FITC 
labelled anti-human CD25 (BioLegend) and 10 nM of PE-labeled tetramer. Then, cells were 
incubated with a Live/Dead fixable Near IR Dead Cell Stain (Life Technologies), 
permeabilized using a Foxp3 Fix/Perm Buffer Set (BioLegend), and stained with Alexa Fluor 
647 labeled anti-human Foxp3 antibody (150D). The tetramer positive gate was set based on 
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the CD3+CD4- population. As validation controls, we found that HLA-DR1-a3135-145 
tetramer+ cells did not bind to HLA-DR1-CLIP tetramers (data not shown). 
 
a3(IV)NC1 peptides and proteins. The human a3135-145 peptide (GWISLWKGFSF), the 
mouse a3136-146 peptide (DWVSLWKGFSF) and control OVA323-339 peptide 
(ISQAVHAAHAEINEAGR) was synthesized at >95% purity, confirmed by HPLC 
(Mimotopes). Recombinant murine a3(IV)NC1 was generated using a baculovirus system21 
and recombinant human a3(IV)NC1 expressed in HEK 293 cells22. The murine a3(IV)NC1 
peptide library, which consists of 28 20 amino acid long peptides overlapping by 12 amino 
acids, was synthesized as a PepSet (Mimotopes). 
 
Reactivity to a3(IV)NC1 T cell epitopes. To measure peptide specific recall responses, 
IFN-g and IL-17A ELISPOTs and [3H]-T proliferation assays were used (Mabtech for human 
ELISPOTs and BD Biosciences for mouse ELISPOTs). To measure pro-inflammatory 
responses of HLA-DR15-a3135-145 tetramer
+ CD4+ T cells in patients with Goodpasture’s 
disease, HLA-DR15-a3135-145 tetramer
+ CD4+ T cells were enumerated then isolated from 
peripheral blood mononuclear cells of patients with Goodpasture’s disease (frozen at time of 
presentation) by magnetic bead separation (Miltenyi Biotec) then co-cultured at a frequency 
of 400 HLA-DR15-a3135-145 tetramer
+ CD4+ T cells/well with 2 x 106 HLA-DR15-a3135-145 
tetramer depleted mitomycin C treated white blood cells and stimulated with either no 
antigens, a3135-145 (10µg/ml) or whole recombinant human a3(IV)NC1 (10µg/ml) in 
supplemented RPMI media (10% male AB serum, 2mM L-Glutamine, 50 µM 2-ME, 100 
U/ml penicillin and 0.1 mg/ml streptomycin) (Sigma-Aldrich). Cells were cultured for 18 
hours at 37˚C, 5% CO2 and the data expressed as numbers of IFN-g or IL-17A spots per well. 
To measure pro-inflammatory responses of HLA-DR15-a3135-145 tetramer
+ CD4+ T cells in 
DR15+ transgenic mice, HLA-DR15-a3135-145 tetramer
+ CD4+ T cells were enumerated then 
isolated from pooled spleen and lymph node cells of DR15+ transgenic mice, immunized with 
mouse a3136-146 10 days prior, by magnetic bead separation then co-cultured at a frequency of 
400 HLA-DR15-a3135-145 tetramer
+ CD4+ T cells/well with 106 HLA-DR15-a3135-145 tetramer 
depleted mitomycin C treated white blood cells and stimulated with either no antigens, mouse 
a3136-146 (10µg/ml), human a3135-145 (10µg/ml), whole recombinant ma3(IV)NC1 (10µg/ml) 
or whole recombinant ha3(IV)NC1 (10µg/ml) in supplemented RPMI media (10% FCS, 
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2mM L-Glutamine, 50 µM 2-ME, 100 U/ml penicillin and 0.1 mg/ml streptomycin). Cells 
were cultured for 18 hours at 37˚C, 5% CO2 and the data expressed as numbers of IFN-g or 
IL-17A spots per well. To determine the immunogenic portions of a3(IV)NC1, mice were 
immunized subcutaneously with either peptide pools (containing a3 aa 1-92, 81-64, or 153-
233; 10 µg/peptide per mouse), the individual peptide or in some experiments ma3136-146 at 
10 µg/mouse in Freund’s complete adjuvant (Sigma-Aldrich). Draining lymph node cells 
were harvested 10 days after immunization and stimulated in vitro (5 x 105 cells/well) with 
no antigen, peptide (10 µg/ml) or whole a3(IV)NC1 (10 µg/ml) in supplemented RPMI 
media (10% FCS, 2mM L-Glutamine, 50 µM 2-ME, 100 U/ml penicillin and 0.1 mg/ml 
streptomycin). For [3H]-T proliferation assays, cells were cultured in triplicate for 72 hours 
with [3H]-T added to culture for the last 16 h. To measure human a3135-145 or mouse a3136-146-
specific responses in CD4+ T cells from naïve transgenic mice or blood of healthy humans, 
we used a modification of a previously published protocol23, 106 CD4+ T cells were cultured 
with 106 mitomycin-treated CD4-depleted splenocytes for 8 days in 96-well plates with or 
without 100 µg/ml of human a3135-145 or mouse a3136-146. Tregs were depleted from mouse 
cultures by sorting out CD4+CD25+ and in humans by sorting out CD4+CD25hiCD127lo cells 
using antibodies and a cell sorter. Cytokine secretion was detected in the cultured 
supernatants by cytometric bead array (BD Biosciences) or ELISA (R&D Systems). To 
determine proliferation, magnetically separated CD4+ T cells were labeled with CTV 
(Thermo Scientific) prior to culture. To measure the expansion of Tfh cells, mice were 
immunized with 100 µg of a3135-145 emulsified in FCA, then boosted 7 days later in FIA. 
Draining lymph node cells were stained with the HLA-DR15-a3135-145 tetramer, CD3, CD4, 
CXCR5, PD-1, CD8 and Live/Dead Viability dye. To determine the potency of HLA-DR1-
a3135-145 tetramer
+
 Tregs, 10
6 cells/well of CD4+CD25- T effectors (Teff) isolated by CD4+ 
magnetic bead and CD25- cell sorting from naïve DR15+DR1+ mice was co-cultured with 
either CD4+CD25+ Tregs with or without depletion of HLA-DR1-a3135-145 tetramer
+
 Tregs 
from DR1+ mice at different concentrations: 0, 12.5 x 103, 25 x 103, 50 x 103, and 100 x 103 
cells/well in the presence of 106 CD4-depleted mitomycin C treated spleen and lymph node 
cells from DR15+DR1+mice in supplemented RPMI media (10% FCS, 2mM L-Glutamine, 50 
µM 2-ME, 100 U/ml penicillin and 0.1 mg/ml streptomycin) containing 100µg/ml of mouse 
a3135-145. To determine proliferation, the CD4
+CD25- Teff cells were labeled with CTV prior 
to culture. Cells were cultured in triplicate for 8 days in 96-well plates. 
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Induction and assessment of experimental autoimmune anti-GBM
4
. HLA transgenic 
mice, on an Fcgr2b-/- background, were immunized with 100 µg of a3135-145 or ma3136-146 
subcutaneously on days 0, 7, and 14; first in Freund’s complete, and then in Freund’s 
incomplete adjuvant. Mice were killed on day 42. Albuminuria was assessed on urine 
collected during the last 24 h by ELISA (Bethyl Laboratories) and expressed as mg per µmol 
urine creatinine. BUN and urine creatinine were measured using an autoanalyser at Monash 
Health. Glomerular necrosis and crescent formation were assessed on PAS-stained sections; 
fibrin deposition using anti-murine fibrinogen antibody (R-4025) and DAB (Sigma); CD4+ T 
cells, macrophages and neutrophils were detected using anti-CD4 (GK1.5), anti-CD68 
(FA/11) and anti-Gr-1 (RB6-8C5) antibodies. To deplete regulatory T cells, mice were 
injected intraperitoneally with 1 mg of anti-CD25 mAb (clone PC61) or rat IgG (control) 2 
days before induction of disease. 
 
Single-cell multiplexed RT-PCR. Individual DR15-a3135-145-specific CD4
+ T cells were 
sorted into wells of a 96-well plate. Multiplex single-cell reverse transcription and PCR 
amplification of TCR CDR3a and CDR3β regions was performed using a panel of TRBV- 
and TRAV-specific oligonucleotides, as described24,25. Briefly, mRNA was reverse 
transcribed in 2.5µl using the Superscript III VILO cDNA Synthesis Kit (Thermo Fisher 
Scientific, Waltham, MA, USA) (containing 1x Vilo reaction mix, 1x superscript RT, 0.1% 
Triton X-100), and incubated at 25°C for 10 min, 42°C for 120 min and 85°C for 5 min. The 
entire volume was then used in a 25µl first-round PCR reaction with 1.5U Taq DNA 
polymerase, 1x PCR buffer, 1.5mM MgCl2, 0.25mM dNTPs and a mix of 25 mouse TRAV 
or 40 human TRAV external sense primers and a TRAC external antisense primer, along with 
19 mouse TRBV or 28 human TRBV external sense primers and a TRBC external antisense 
primer (each at 5 pmol µl−1), using standard PCR conditions. For the second-round nested 
PCR, a 2.5 µl aliquot of the first-round PCR product was used in separate TRBV- and 
TRAV-specific PCRs, using the same reaction mix described above; however, a set of 25 
mouse TRAV or 40 human TRAV internal sense primers and a TRAC internal antisense 
primer, or a set of 19 mouse TRBV or 28 human TRBV internal sense primers and a TRBV 
internal antisense primer, were used. Second-round PCR products were visualized on a gel 
and positive reactions were purified with ExoSAP-IT reagent. Purified products were used as 
template in sequencing reactions with internal TRAC or TRBC antisense primers, as 
described. TCR gene segments were assigned using the IMGT (International 
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ImMunoGeneTics) database26. In mouse experiments, 3 mice were pooled per HLA and the 
number of sequences obtained were for TRAV (DR15, n = 81; DR1 n = 84), for TRBV 
(DR15, n = 100; DR1 n = 87), for TRAJ (DR15, n = 81; DR1 n= 84) and for TRBJ (DR15, n 
= 100; DR1 n = 87).  
 
RT-PCR for tTreg genes. Red blood cell lysed splenocytes from DR1+ and DRB15+DR1+ 
mice were sorted based on surface expression of CD4 and CD25 and either DR1-a3135-145 
tetramer positive or negative into three groups, 1) CD4+CD25-HLA-DR1-a3135-145 tetramer
- T 
conventional (Tconv) cells, 2) CD4+CD25+HLA-DR1-a3135-145 tetramer
-
 Tregs, and 3) 
CD4+CD25+HLA-DR1-a3135-145 tetramer
+
 Tregs. A minimum of 1000 cells were sorted. 
Immediately after sorting the RNA was isolated and cDNA generated using the Cells to Ct 
Kit (Ambion) followed by a preamplification reaction using Taqman Pre Amp Master Mix 
(Applied Biosystems) which preamplified the following cDNAs: Il2ra, Foxp3, Ctla4, 
Tnfrsf18, Il7r, Sell, Pdcd1, Entpd1, Cd44, Tgfb3, Itgae, Ccr6, Lag3, Lgals1, Ikzf2, Tnfrsf25, 
Nrp1, Il10. The preamplified cDNA was used for RT-PCR reactions in duplicate using 
Taqman probes for the aforementioned genes. Each gene is expressed relative to 18s, 
logarithmically transformed and presented as a heat map. 
 
Purification of MHC bound peptides. The EBV transformed human B lymphoblastoid cell 
lines IHW09013 (SCHU, DR15-DR51-DQ6) and IHW09004 (JESTHOM, DR1-DQ5) were 
maintained in RPMI (Invitrogen) supplemented with 10% FCS, 50 IU/ml penicillin and 50 
µg/ml streptomycin. Confirmatory tissue typing of these cells was performed by the 
Victorian Transplantation and Immunogenetics Service. The B cell hybridoma LB3.1 (anti-
DR) was grown in RPMI-1640 with 5% FCS at 37°C and secreted antibody purified using 
protein A sepharose (BioRad). HLA-DR presented peptides were isolated from naïve 
DR15+.Fcgr2b+/+ or DR1+.Fcgr2b+/+ mice. Spleens and lymph nodes (pooled from five mice in 
each group) or frozen pellets of human BLCLs (triplicate samples of 109 cells) were 
cryogenically milled and solubilised as previously described12,27, cleared by 
ultracentrifugation and MHC peptide complexes purified using LB3.1 coupled to protein A 
(GE Healthcare). Bound HLA complexes were eluted from each column by acidification with 
10% acetic acid. The eluted mixture of peptides and HLA heavy chains was fractionated by 
RP-HPLC as previously described10. 
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LC-MS/MS acquisition and analysis. Peptide-containing fractions were analysed by nano-
LC-MS/MS using a ThermoFisher Q-Exactive Plus mass spectrometer (ThermoFisher 
Scientific, Bremen, Germany) operated as described previously10. LC-MS/MS data was 
searched against the mouse or human proteomes (Uniprot/Swissprot v2016_11) using the 
ProteinPilot™ software (SCIEX) and resulting peptide identities subject to strict 
bioinformatic criteria including the use of a decoy database to calculate the false discovery 
rate (FDR)28. A 5% FDR cut-off was applied, and the filtered dataset was further analysed 
manually to exclude redundant peptides and known contaminants as previously described29. 
The mass spectrometry data have been deposited to the ProteomeXchange Consortium via 
the PRIDE30 partner repository with the dataset identifier PXD005935. 
 
Motif Analysis. Minimal core sequences found within nested sets of peptides with either N- 
or C-terminal extensions were extracted and aligned using MEME 
(http://meme.nbcr.net/meme/), where motif width was set to 9-15 and motif distribution set to 
‘one per sequence’31. Graphical representation of the motif was generated using IceLogo32. 
 
Crystallization and structure determination. Crystal trials were set-up at 21°C using the 
hanging drop vapour diffusion method. Crystals of HLA-DR15-a3135-145 were grown in 25% 
PEG 3350, 0.2M KNO3 and 0.1M Bis-Tris-propane (pH 7.5), and crystals of HLA-DR1-
a3135-145 were grown in 23% PEG 3350, 0.1M KNO3, and 0.1M bis-tris-propane (pH 7.0). 
Crystals were washed with mother liquor supplemented with 20 % ethylene glycol and flash 
frozen in liquid nitrogen prior to data collection. Data was collected using the MX1 
beamline33 at the Australian Synchrotron, and processed with iMosflm and Scala from the 
CCP4 program suite34. The structures were solved by molecular replacement in PHASER35 
and refined by iterative rounds of model building using COOT36 and restrained refinement 
using Phenix37 (see Extended Data Table 2 for data collection and refinement statistics). 
 
Statistics. For normally distributed data, an unpaired two-tailed t-test (when comparing two 
groups) or one-way ANOVA (Tukey post-test) was used. For non-normally distributed data, 
non-parametric tests (Mann-Whitney for two groups or Kruskal-Wallis test with Dunn’s 
multiple comparison) were used. Statistical analyses, except for TCR usage, was by 
GraphPad Prism (GraphPad Software Inc.). For each TCR type/region (TRAV, TRBV, 
TRAJ, TRBJ), we compared the TCR distribution (frequencies of different TCRs) between 
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DR15 and DR1 using Fisher's exact test. This was applied to both mice and human samples. 
The p-values associated with those TCR distributions are indicated above the pie-charts. To 
correct for multiple testing for individual TCR, we used Holm’s method. *P<0.05, **P<0.01, 
***P<0.001. 
 
Data Availability Statement 
The data that support the findings of this study are available from the corresponding authors 
upon request. Self-peptide repertoires have been deposited in the PRIDE archive with the 
accession code PXD005935. Structural information has been deposited in PDB under 
accession codes 5V4M and 5V4N. 
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EXTENDED DATA TABLES 
Extended Data Table 1. Clinical details of patients with anti-GBM glomerulonephritis 
Patient Gender Age Serum creatinine 
(µmol/L) 
Treatment at sampling 
GP1 Male 72 1300 CS, CYC 
GP2 Female 19 184 Nil 
GP3 Male 55 1991 * CS, PLEX 
GP4 Female 72 369 CS, PLEX, CYC 
GP5 Female 86 600 * Nil 
GP6 Male 72 730 CS, PLEX, CYC 
GP7 Female 25 212 CS, PLEX, CYC 
GP8 Female 79 492 Nil 
* Receiving hemodialysis at the time of sampling  
CS, corticosteroids; PLEX, plasma exchange, CYC, cyclophosphamide 
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Extended Data Table 2: Data collection and refinement statistics 
 
 HLA-DR15-a3135-145 
(5V4M) 
HLA-DR1-a3135-145 
(5V4N) 
Data collection   
Space group P1 P212121 
Cell dimensions     
    a, b, c (Å) 67.59, 79.01, 95.82 82.09, 118.41, 120.88  
    a, b, g (°)  87.64, 73.29, 89.97 90, 90, 90 
Resolution (Å) 48.32-2.1 (2.18-2.1)a 53.831-3.405 (3.527-3.405) a 
Rmerge 0.129 (0.709) 0.1099 (0.3648) 
I/s(I) 9.5 (2.3) 6.04 (2.60) 
CC1/2
 0.995(0.692) 0.942 (0.651) 
Completeness (%) 96.3 (95.5) 99.0 (99.0) 
Redundancy 5.4 (5.3) 2.0 (2.0) 
   
Refinement   
Resolution (Å) 48.32-2.1 53.831-3.405 
No. reflections 106601 16628 
Rwork / Rfree 0.2167/0.2440 0.2121/0.2629 
No. atoms 13352 6194 
    Protein 12518 6152 
    Ligand/ion 180  42 
    Water 654 - 
B factors   
    Protein 34.96 67.59 
    Ligand/ion 71.88 113.48 
    Water 37.15 - 
R.m.s. deviations   
    Bond lengths (Å) 0.003 0.003 
    Bond angles (°) 0.67 0.72 
Number of crystals for each structure should be noted in footnote.  
a Values in parentheses are for highest-resolution shell. 
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Extended Data Table 3. HLA type of healthy human donors (HD, healthy donor) 
 
DR15 homozygotes 
Donor A B C Bw DRB1 DQBI DPB1 DRB5 
HD1 1, 24 24, 8 7  15:01 6 4, 16 1:01 
HD2 2, 3 7, 15 3, 7 6 15:01 6 4 1:01 
HD3 2, 3 7, 51 7, 14 4, 6 15:01 6   
HD4 3, 11 7, 47 6, 7 4, 6 15:01 6   
HD5 1, 29 7 7 6 15:01    
HD6 1, 2 7 7 6 15:01 6  1:01 
 
DR1 homozygotes 
 A B C Bw DRB1 DQBI DPB1 DRB5 
HD7 3, 11 35, 62 3, 4  01:01 5   
HD8 3, 24 51, 40 3, 14 4, 6 01:01    
HD9 2, 3 51, 56 1 4, 6 01:01 5   
HD10 2, 3 27, 35  4, 6 01:01 5   
HD11 3, 26 27, 35 1, 4 4, 6 01:01 5 4  
 
DR15/DR1 heterozygotes 
 A B C Bw DRB1 DQBI DPB1 DRB5 
HD12 3, 29 7, 35 04, 07 6 01:01, 15:01 5, 6 4 1:01 
HD13 3, 26 7, 27 1, 7 4, 6 01:01, 15:01 5, 6 4 1:01 
HD14 03, 26 7, 49 7 4, 6 01:01, 15:01 5, 6 3, 4 1:01 
HD15 03 7, 14 7, 8  01:01, 15:01 5, 6   
HD16 02, 03 7, 51   4, 6 01:01, 15:01 5, 6  1:01 
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EXTENDED DATA FIGURE LEGENDS 
 
Extended Data Figure 1: HLA-DR15-a3135-145 tetramer
+
 CD4
+
 T cells from humans and 
mice respond to a3135-145 and to whole a3(IV)NC1. a, HLA-DR15-a3135-145 tetramer
+ 
CD4+ T cells isolated from patients with Goodpasture’s disease (n=8) respond to a3135-145 
and recombinant human (rh)a3(IV)NC1. HLA-DR15-a3135-145 tetramer
+ CD4+ T cells were 
isolated by magnetic bead separation from the blood of patients with Goodpasture’s disease, 
then cultured at a frequency of 400 HLA-DR15-a3135-145 tetramer
+ CD4+ T cells per well in 
the presence of mitomycin C treated HLA-DR15-a3135-145 tetramer
+ cell depleted white blood 
cells and either ha3135-145 or rha3(IV)NC1. Antigen specific responses were assessed by 
ELISPOTs for IFN-g and IL-17A and expressed as numbers of spots per well. b, To induce 
experimental autoimmune anti-GBM disease, DR15+.Fcgr2b-/- mice (n=5) were immunized 
with ha3135-145 on days 0, 7 and 14. Disease was measured at day 42, by which time 
DR15+.Fcgr2b-/- mice develop kidney disease similar to human Goodpasture’s disease including 
glomerular segmental necrosis, crescents (PAS stain), linear IgG deposition (direct 
immunofluorescence) and pathological albuminuria. Each dot represents one mouse. 
Photomicrographs taken at 400x depict a crescentic glomerulus with segmental necrosis 
(bottom left panel) and linear glomerular IgG deposition (bottom right panel) seen in 
DR15+.Fcgr2b-/- mice immunized with ha3135-145. Scale bars = 30µm. c, HLA-DR15-a3135-145 
tetramer+ CD4+ T cells isolated from DR15+.Fcgr2b+/+ mice respond to mouse (m)a3136-146, 
ha3135-145, rma3(IV)NC1 and rha3(IV)NC1. HLA-DR15-a3135-145 tetramer
+ CD4+ T cells 
were isolated by magnetic bead separation from pooled spleen and lymph node cells of two 
DR15+ transgenic mice 10 days after immunisation with ma3136-146 (DWVSLWKGFSF, 
ha3135-145 GWISLWKGFSF) then cultured at a frequency of 400 HLA-DR15-a3135-145 
tetramer+ CD4+ T cells per well in the presence of mitomycin C treated HLA-DR15-a3135-145 
tetramer+ cell depleted spleen and lymph node cells. Antigen specific responses were 
assessed by ELISPOTs for IFN-g and IL-17A and expressed as numbers of spots per well. 
*
P<0.05; **P<0.01; ***P<0.001 by Kruskal-Wallis test (a and c) or Mann-Whitney U test (b). 
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Extended Data Figure 2: Immune responses in DR15
+
DR1
+.Fcgr2b+/+
 mice. a, Naïve 
FcgRIIb intact HLA transgenic mice have similar immune properties. Shown are the 
proportion of splenocytes expressing HLA-DR; HLA-DR15 and HLA-DR1 intensities (MFI) 
in naïve DR15+ (n=4), DR1+ (n=4) and DR15+DR1+ transgenic mice (n=5) showing half the 
amount of expression in DR15+DR1+ relative to its single transgenic counterpart; total 
number of splenocytes; proportion of CD4+ and CD4+Foxp3+ splenocytes; total number of 
lymph node cells retrieved from the brachial, axillary and inguinal lymph nodes; proportion 
of CD4+ and CD4+Foxp3+ lymph node cells and the overall Vb repertoire of HLA transgenic 
mice showing no skewing of any one Vb chain. Data expressed as mean±s.e.m., analysed by 
ANOVA. b, Co-expression of HLA-DR1 abrogates pro-inflammatory high autoreactivity to 
peptide ma3129-148 but not to other parts of a3(IV)NC1. FcgRIIb intact DR15
+, DR1+ and 
DR15+DR1+ mice were immunized with murine a3 peptide pools (see Methods for peptide 
pools) (n = 5 each group) and responses to individual 20-mer peptides measured by 
restimulating the draining lymph node cells ex vivo (x-axis numbering represents the N-
terminus amino acid number of the individual 20-mer peptide) using [3H]-T proliferation 
assays, and IFN-g and IL-17A ELISPOTs. Each dot represents the mean response from 
triplicate determinations in an individual mouse and each bar represents the mean response in 
each group. Blue bars indicate no reactivity (SI < 2; spots < 5), yellow bars indicate low 
reactivity (2 < SI < 5; 5 < spots < 25), and red bars indicate high reactivity (SI > 5, spots > 
25). 
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Extended Data Figure 3: Self-peptide repertoires of HLA-DR15/DR51 and HLA-DR1 
using human cell lines, with electron density maps for the α3135-145 peptide. Peptide 
repertoire analysis of 9-mer core sequences of HLA-DR presented self-peptides in the human 
BLCLs IHW09013 (DR15+/DR51+) and IHW09004 (HLA-DR1+). Amino acid frequencies in 
each peptide position p1 to p9 were plotted using IceLogo32, with the human proteome as the 
frequency reference. Relatively enriched amino acids are plotted above the horizontal bar, 
and depleted amino acids below. The scale of each letter is proportional to the frequency 
difference to the reference. Peptides were eluted from a, IHW09013 HLA-DR15+/DR51+ 
cells, and b, from IHW09004 HLA-DR1+ cells. For HLA-DR1, preferred amino acids at p1, 
p4, p6, p7 and p9 are similar between the human and mouse DR1+ cells. For DR15+/DR51+ 
human cells compared to DR15+ mouse APCs, the difference at p9, with Lys and Arg being 
the most frequently bound residues, reflects the known DR51-related motif. c, d, Simulated 
annealing 2Fobs-Fcalc omit maps for the peptide of c, HLA-DR15 and d, HLA-DR1. e, f, Final 
2Fobs-Fcalc maps for the peptide in e, HLA-DR15 and f, HLA-DR1. Electron density maps 
contoured at 1s are shown as blue mesh. 
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Extended Data Figure 4: HLA-DR1-a3135-145 tetramer
+
 CD4
+
 T cells have differential 
TRAJ usage and the CD4
+
CD25
+
 Tregs gene transcription profile is similar to that of 
thymically derived Tregs (tTregs). a, The TRAJ and TRBJ usage of a3135-145-specific CD4
+ 
T cells was compared using the HLA-DR15-a3135-145 tetramer (in naïve DR15
+ Fcgr2b+/+ mice) 
and the HLA-DR1-a3135-145 tetramer (in naïve DR1
+.Fcgr2b+/+ mice) by single cell sequencing. 
a3135-145-specific CD4
+ tetramer+ T cells from naïve DR15+ (n=3) and DR1+ (n=3) transgenic 
mice were pooled then single cell sorted, TCR genes amplified by multiplex PCR, then 
sequenced to determine TRAJ (DR15, n=81; DR1 n=84) and TRBJ (DR15, n=100; DR1 
n=87) usage. For each TCR type/region (TRAV, TRBV, TRAJ, TRBJ; TRAV and TRBV 
shown in Fig. 2g), we compared the TCR distribution (frequencies of different TCRs) 
between DR15 and DR1, *** P<0.001 by Fisher’s exact test. b, HLA-DR1-a3135-145 tetramer
- 
CD4+CD25- Tconv, HLA-DR1-a3135-145 tetramer
-CD4+CD25+ Tregs and HLA-DR1-a3135-145 
tetramer+ CD4+CD25+ Tregs were isolated from naïve FcgRIIb intact DR1+ or DR15+DR1+ 
transgenic mice by flow cytometry, RNA extracted and the relative expression of tTreg genes 
expressed relative to 18S. The HLA-DR1-a3135-145 tetramer
+ CD4+CD25+ Tregs express 
genes consistent with a tTreg origin, similar to other Tregs that are not a3135-145-specific from 
the same mice. 
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Extended Data Figure 5: Responses and effects of antigen specific DR1-associated 
Tregs. a, Measurement of pro- and anti-inflammatory mouse (m)a3136-146-specific CD4
+ T 
cell responses by ex vivo stimulation. CD4+ T cells, isolated and pooled from naïve 
DR15+.Fcgr2b+/+ (n=2), DR1+.Fcgr2b+/+ (n=2) and DR15+DR1+.Fcgr2b+/+ (n=2) transgenic mice 
were cultured for 8 days in the presence of ma3136-146 and mitomycin C treated syngeneic 
CD4+ cell-depleted splenocytes. Tregs were depleted by removing CD4+CD25+ T cells by 
cell sorting. IFN-g, IL-17A, IL-6 and IL-10 were measured in the cultured supernatant by 
cytometric bead array and TGF-b by ELISA. The experiment was performed in triplicate and 
the data presented as mean±s.e.m. To measure a3136-146-specific CD4
+ Treg proliferation, 
CD4+ T cells were labelled with CTV then stained with Foxp3 on day 8. Results were similar 
to those performed using human (h)a3135-145 presented in Fig. 3b. b, HLA-DR1-a3135-145-
specific Tregs are potent suppressors of HLA-DR15-a3135-145 induced pro-inflammatory 
responses. CD4+CD25- T cells were isolated and pooled from naïve DR15+DR1+.Fcgr2b+/+ 
mice (n=2) and co-cultured with either CD4+CD25+ Tregs (which included HLA-DR1-a3135-
145 tetramer
+ Tregs) or CD4+CD25+ HLA-DR1-a3135-145 tetramer
- from naïve DR1+.Fcgr2b+/+ 
mice (n=4) in the presence of ma3136-146 and CD4
+ cell-depleted spleen and lymph node cells 
from DR15+DR1+ mice. Cells were cultured for 8 days. a3135-145-specific CD4
+CD25- cell 
proliferation was measured by labelling only the DR15+DR1+ derived naïve CD4+CD25- cells 
with CTV; IFN-g, IL-17A, IL-6 and IL-10 were measured in the cultured supernatant by 
cytometric bead array. In the absence of CD4+CD25+ HLA-DR1-a3135-145 tetramer
+ cells, the 
capacity of Tregs to prevent the induction of autoreactivity to a3135-145 was impaired. These 
experiments were performed in triplicate and the data presented as mean±s.e.m. c, Treg 
depletion expands HLA-DR15-a3135-145-specific T follicular helper (Tfh) cells. Anti-CD25 
mAbs (or control Rat IgG) were administered 2 days prior to ha3135-145 immunization and 
boost (n=4 per group), then the number of a3135-145-specific PD-1
+CXCR5+ Tfh cells 
enumerated in the draining lymph nodes. FACS plots show the expansion of PD1+CXCR5+ 
Tfh cells after Treg depletion and the detection of HLA-DR15-a3135-145-specific cells within 
that population. *P < 0.05; ** P < 0.01; *** P < 0.001 by Mann-Whitney U test (a and b) or 
Kruskal-Wallis test (c). 
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Extended Data Figure 6: In vivo Treg depletion in HLA transgenic mice. a, Efficiency 
and duration of Treg depletion using anti-CD25 mAb (clone PC61) in DR15+DR1+.Fcgr2b-/- 
mice. Timeline showing the administration of anti-CD25 mAb 2 days before immunizing 
mice with human (h)a3135-145. Detection of CD4
+foxp3+ Tregs in the blood showing depletion 
of Tregs at days 7 and 14 in mice that received the anti-CD25 mAb (n=5 each group). White 
bars represent mice that received control antibodies and solid bars represent mice that 
received anti-CD25 mAb. b, DR15+.Fcgr2b-/- (n=6 each group), DR1+.Fcgr2b-/- (n=4 each group) 
and DR15+DR1+.Fcgr2b-/- (n=6 each group) mice immunized with a control peptide, OVA323-339 
do not develop renal injury. Functional injury measured by albuminuria and blood urea 
nitrogen; and histological injury assessed by scoring of PAS stained histological sections for 
segmental necrosis and glomerular crescents. Representative PAS stained histological 
sections. White bars represent mice that received control antibodies and solid bars represent 
mice that received anti-CD25 mAb. c, Treg depletion leads to cell mediated injury in 
DR15+DR1+.Fcgr2b-/- mice (further data collected in the experiment presented in Fig. 4a). Anti-
CD25 mAbs (or control Rat IgG) were administered 2 days prior to the induction of 
experimental autoimmune anti-GBM GN by ha3135-145 immunization in DR15
+.Fcgr2b-/- (n=6 
per group), DR1+.Fcgr2b-/- (n=4 per group) and DR15+DR1+.Fcgr2b-/- (n=8 [Treg intact], 9 [Treg 
depleted]) mice. Cell mediated injury was assessed by quantifying glomerular fibrin 
deposition and enumerating and inflammatory cell infiltrates (CD4+ T cells, macrophages and 
neutrophils). Renal inflammation was measured by RT-PCR of inflammatory cytokines 
(TNF, IL-6 and IL-1a) on kidney digests. Scale bars = 30 µm. d, Repeating the experiment 
presented in Fig. 4a using mouse (m)a3136-146 instead of ha3135-145 as the immunogen showed 
similar results (DR15+.Fcgr2b-/-, n=6 [Treg intact], 7 [Treg depleted]; DR1+.Fcgr2b-/- , n=4 [Treg 
intact], 5 [Treg depleted]; and DR15+DR1+.Fcgr2b-/-, n=6 per group), with the emergence of 
autoimmune anti-GBM glomerulonephritis in DR15+DR1+.Fcgr2b-/- mice only after Treg 
depletion. Values are mean±s.e.m.; *P < 0.05; ** P < 0.01; *** P < 0.001 by Mann-Whitney U 
test (a-d). 
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Extended Data Figure 7: Single cell sequencing data from healthy humans and 
Goodpasture’s patients validate and corroborate findings in HLA transgenic mice. a, 
Comparing the TCR usage of a3135-145-specific CD4
+ T cells using the HLA-DR15-a3135-145 
tetramer and the HLA-DR1-a3135-145 tetramer by TCR single cell sequencing, TRAV (DR15, 
n=20; DR1 n=28), TRBV (DR15, n=20; DR1 n=24), TRAJ (DR15, n=20; DR1 n=28) and 
TRBJ (DR15, n=20; DR1 n=24). For each TCR type/region (TRAV, TRBV, TRAJ, TRBJ), 
we compared the TCR distribution (frequencies of different TCRs) between DR15 and DR1. 
*
P < 0.05 by Fisher’s exact test. The full HLA-types of the DR15 homozygous donor (HD1) 
and the DR1 homozygous donor (HD7) are listed in Extended Data Table 3. b, In anti-GBM 
patients, a3135-145-specific T cells clonally expand. a3135-145-specific CD4
+ T cells from the 
blood of two anti-GBM patients were single cell sorted using HLA-DR15-a3135-145 tetramer 
by flow cytometry. TCR genes were amplified by multiplex PCR, then sequenced to 
determine TRAV (n=12 and 45) and TRBV usage (n=16 and 44) and CDR3 amino acid 
sequence. Differently coloured slices within the pie chart highlights the TRAV or TRBV in 
which repeated CDR3 sequences were found. All CDR3 sequences within the highlighted 
TRAV or TRBV are shown in coloured letters (1 row = 1 CDR3 sequence). 
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